Our Practices
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Whistleblower Claims
Current Investigations
General
Drug Injury
- Actos
- Accutane
- Fosamax
- GranuFlo/NaturaLyte
- Gadolinium
- Ocella, Yasmin, Yaz
- Pradaxa
- Sleeping Pills
- SSRIs
- Topamax
- Tylenol
- Zithromax/Z-pack
- Zocor/Simvastatin
Medical Devices
- Da Vinci Robot
- DePuy Hip Recall
- Mirena
- Stryker Recall
- Stryker Lawsuit
- Transvaginal Mesh
- Zimmer Hip Implant
Product Liability
- Aveeno Lawsuit
- Atlas Roofing Lawsuit
- Avon/Clarins Products
- AZEK Decking
- Chinese Drywall
- Chrysler Lock-Ups
- Demilec Insulation
- Electrolux Lawsuit
- Energy Drink Lawsuit
- Flushmate Systems
- Ford 5.4L Engine
- Ford & Mercury Transmissions
- Ford Mileage Claims
- GAF Decking
- Jeld-Wen Low E
- LP/ABTCO TrimBoard
- Norcold Lawsuit
- Pozzi and Jeld-Wen
- Remington Lawsuit
- TimberTech Decking
- Toyota Power Windows
- Trex Decking Lawsuit
Food
Pending Settlements
Category : Osteoporosis
FDA Panels Recommend Clearer Fosamax Labels
September 19th, 2011
Fosamax, the subject of an ongoing Seeger Weiss investigation, is one of the four brands of bisphosphonates discussed in two advisory panels to the FDA on September 9. Bisphosphonates, drugs prescribed to women at risk of osteoporosis, have in recent years been demonstrated to cause fractures to the femur. Examining the mounting evidence, including the testimony of 18 victims who suffered atypical femoral fractures after taking the medication, the panels voted to recommend more specific instructions for how long Fosamax and other bisphosphonates should be used.
Learn More about our Fosamax Investigation
Subscribe to our RSS
